| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 174,60 | 175,40 | 22:06 | |
| 174,40 | 175,10 | 22:00 |
| Stück | Geld | Kurs | Brief | Stück |
|---|---|---|---|---|
| 176,90 | 3 | |||
| 176,70 | 52 | |||
| 176,50 | 3 | |||
| 176,40 | 18 | |||
| 175,20 | 49 | |||
Quelle: [URL] https://aktienkurs-orderbuch.finanznachrichten.de/56s1.htm [/URL] | ||||
| 67 | 174,40 | |||
| 3 | 173,00 | |||
| 49 | 172,90 | |||
| 3 | 172,80 | |||
| 3 | 172,60 | |||
| 1.023 | 0,000 | |||
| Summe Aktien im Kauf | Verhältnis | Summe Aktien im Verkauf | ||
| 1.148 | 0,109 | 125 | ||
| Uhrzeit | Aktienkurs | Stück |
|---|---|---|
Keine Umsätze verfügbar. | ||
| Tagesumsatz Xetra | - | 0 |
Angaben in grüner Schrift zeigen, dass der Aktienkurs im Vergleich zum vorherigen Kurs gestiegen ist. Angaben in roter Schrift zeigen gefallene Börsenkurse.
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | Warum diese Biotech-Aktie nach der Chip-Rallye spannend werden könnte | Small- & Micro Cap Investment | |||
| Mo | JPMORGAN stuft Sartorius Stedim Biotech auf 'Overweight' | 806 | dpa-AFX-Analyser | NEW YORK (dpa-AFX Analyser) - Die US-Bank JPMorgan hat die Einstufung für Sartorius Stedim mit einem Kursziel von 260 Euro auf "Overweight" belassen. Insgesamt erwartet Richard Vosser für den Laborausrüster... ► Artikel lesen | |
| 01.06. | Sartorius Stedim Biotech SA: Declaration Relative to the Number of Shares and Voting Rights Making up the Issued Capital | 481 | Dow Jones News | DJ Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Sartorius Stedim Biotech SA
Sartorius Stedim Biotech SA: DECLARATION... ► Artikel lesen | |
| 06.05. | RBC stuft Sartorius Stedim Biotech auf 'Outperform' | 730 | dpa-AFX-Analyser | NEW YORK (dpa-AFX Analyser) - Die kanadische Bank RBC hat Sartorius Stedim mit einem Kursziel von 210 Euro auf "Outperform" belassen. Analyst Charles Weston nahm mit Blick auf die jüngsten Quartalszahlen... ► Artikel lesen | |
| SARTORIUS STEDIM BIOTECH Aktie jetzt für 0€ handeln | |||||
| 05.05. | Sartorius Stedim Biotech SA: Declaration Relative to the Number of Shares and Voting Rights Making up the Issued Capital | 446 | Dow Jones News | DJ Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Sartorius Stedim Biotech SA
Sartorius Stedim Biotech SA: DECLARATION... ► Artikel lesen |
| Zeit | Aktuelle Nachrichten | Medien | ||
|---|---|---|---|---|
| 13:06 | Fortrea Holdings Inc: Fortrea Names Jason Knoblauch as Chief Financial Officer | GlobeNewswire (Europe) | DURHAM, N.C., June 26, 2026 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the "Company"), a leading global contract research organization (CRO), today announced that Jason Knoblauch has been appointed... ► Artikel lesen | |
| 18:33 | VALBIOTIS SA: Valbiotis announces the success of its capital increase of EUR10.2M | Dow Jones News | DJ VALBIOTIS SA: Valbiotis announces the success of its capital increase of EUR10.2M
VALBIOTIS SA
VALBIOTIS SA: Valbiotis announces the success of its capital increase of EUR10.2M
26-Jun-2026... ► Artikel lesen | |
| 13:50 | OS Therapies: OS Animal Health Announces Peer-Reviewed Publication of Clinical Trial Data for OST-HER2 Plus Palliative Radiation as Frontline Treatment in Canine Osteosarcoma | Newsfile | 20% of OST-HER2 treated dogs survived 2-year vs. 1% in control group (p = 0.00995)Over 15,000 dogs per year diagnosed with osteosarcomaCompany expects to submit U.S. Department of Agriculture meeting... ► Artikel lesen | |
| 15:06 | Vifor International AG (CSL Vifor): CHMP recommends revoking marketing authorisation for TAVNEOS (avacopan) in the European Union | PR Newswire | Recommendation follows an Article 20 non-pharmacovigilance procedure Patients currently on TAVNEOS treatment should consult their treating physician ST. GALLEN, Switzerland, June 26, 2026... ► Artikel lesen | |
| 15:48 | CSL Vifor: CHMP Recommends Revocation Of EU Marketing Authorisation For TAVNEO | AFX News | THOUSAND OAKS (dpa-AFX) - Vifor Fresenius Medical Care Renal Pharma and CSL (CSL.AX) announced that the European Medicines Agency's Committee for Medicinal Products for Human Use has recommended... ► Artikel lesen |